News | August 04, 2010

Imaging Agent in Development May Aid Cancer Imaging

August 3, 2010 — New cancer-specific imaging compounds may help enhance the imaging capabilities of positron emission tomography (PET) or single photon emission computed tomography (SPECT).

GenSpera’s technology platform combines a potent, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that releases the drug only within the tumor. Unlike standard cancer drugs, thapsigargin kills cells independent of their division rate, making it effective at killing all fast- and slow-growing cancers and cancer stem cells. GenSpera’s pro-drug platform is the subject of seven issued patents with four additional patents pending.

GenSpera Inc. said today it acquired a patent application for new medical imaging technology from the Johns Hopkins University and the University of Copenhagen. This technology will be coupled with the company’s patented tumor-targeted peptides, which incorporates derivatives of thapsigargin.

“These thapsigargin derivatives are a natural extension of our work with G-202 and G-115, the lead cancer drugs in GenSpera’s pipeline,” said Dr. Soren Brogger Christensen, professor of pharmacognosy at the University of Copenhagen and co-inventor of the technology. “I am delighted that GenSpera has acquired this application as they have the vision, know-how and determination to bring these important potential medical applications to realization.”

In early 2010, GenSpera initiated a phase I clinical trial targeting solid tumor cancers with its lead drug, G-202, at Johns Hopkins University and the University of Wisconsin. The company anticipates completion of phase I trials in the second quarter of 2011.

Upon successful completion of its phase I trial, GenSpera expects to initiate multiple phase II trials for G-202 in several different types of cancer. The company’s second drug, G-115, will directly target prostate cancer. The company anticipates filing an application to commence phase I trials of G-115 in third quarter of 2011.

For more information: www.genspera.com

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....